Table 1.

Relevant clinical and laboratory parameters of the 2 patients with severe COVID-19 and acute tubular injury and oxalate nephropathy after a kidney biopsy procedure

Clinical and laboratory parameters	Patient 1	Patient 2
Treatments
Vitamin C total dose, g	112	160
Hydroxychloroquine dose, d	400 mg bid (ND)	400 mg bid (24)
Darunavir/cobicistat dose, d	800/150 mg (unclear)	800/150 mg (7)
Lopinavir/ritonavir, d	—	200/50 mg (unclear)
Azithromycin dose, d	ND	500 mg (5)
Tocilizumab	Yes	—
Steroids	Yes	Yes
Parenteral nutrition	—	—
Enteral nutrition	Yes	Yes
Interleukin-6 zenith, pg/ml	—	123.5
Polymerase chain reaction zenith, mg/dl	44.4	28.3
Days intubated	15	15
Need for inotropes	Yes	Yes
Anuria, d	10	20
Total time of kidney replacement treatment, d	33	31
S creatinine at admission, mg/dl	1	1.1
S creatinine at kidney biopsy procedure, mg/dl	5.85	6.5
Proteinuria, g/d	0.2	1.2
Microhematuria	No	Yes
Diuresis at kidney biopsy procedure, ml/d	2000	3700
S creatinine at hospital discharge, mg/dl	4	4.44
Diuresis at hospital discharge, ml/d	1800	3900
24-h urine oxalate, d 50	—	42 mg

b.i.d., twice a day; COVID-19, coronavirus disease 2019; ND, not determined, S, serum.